BingLiang Ph.D.

Partner

Silicon Valley + 1.650.687.4168

Connect:

Share

Dr. Bing Liang represents biotechnological and pharmaceutical companies on the procurement and protection of intellectual property, particularly in the areas of biologics and diagnostics. Bing drives global intellectual property strategies for high-value innovative medicines, with a proven track record of success creating strategic patent assets covering some of the world's most valuable life-saving medicines, including CARVYKTI®, PALYNZIQ®, PADCEV™, VENCLEXTA®, NUPLAZID®, POMALYST®, REVLIMID®, and OTEZLA®.

She prepares and prosecutes patent applications in a variety of technologies including antibody therapeutics, immuno-oncology therapeutics, cell and gene therapies, genome editing, antisense therapeutics, enzyme replacement therapies, stem cells, and genome sequencing.

Bing advises patentability, validity, infringement, and freedom-to-operate issues and performs due diligence evaluations of patent portfolios in connection with venture capital and private equity financings, collaborations, and/or partnering deals. She is experienced in licensing agreements.

Her practice also includes various post-grant proceedings before the Patent Trial and Appeal Board (PTAB), including inter partes reviews (IPRs).

Her representative clients include AbbVie, Merck, BioMarin Pharmaceutical, Bristol Myers Squibb (Celgene), Legend Biotech, and Astellas, as well as other start-up companies, established companies, academic institutions, and investment firms.

Prior to practicing law, Bing obtained her Ph.D. in biomedical sciences from Mount Sinai School of Medicine of New York University, where her research focused on chromatin remodeling and its functions in maintaining genome integrity. During this time she discovered important roles of chromatin remodeling complexes in DNA damage repair and telomere length maintenance. Bing has extensive technical experience in biochemistry, molecular biology, genetics, immunology, and cell biology.

Experience

  • Merck develops global patent portfolio related to certain antibodies for treatment of cognitive disordersJones Day is representing Merck & Co., Inc. in the development and prosecution of global patent portfolios related to certain antibodies that are being developed for the treatment and prevention of various cognitive disorders.
  • Merck develops global patent portfolio related to certain bispecific antibodiesJones Day is representing Merck & Co., Inc. in the development and prosecution of a global patent portfolio related to certain bispecific antibodies.
  • Nanjing Legend Biotech establishes global patent portfolio for CAR-T therapeuticsJones Day represents Nanjing Legend Biotech Co., Ltd et al in the development and prosecution of global patent portfolios related to chimeric antigen receptor T cell (CAR-T) and other cellular therapeutics, including CARVYKTI ® and other clinical trial candidates.
  • Celgene acquired by Bristol-Myers Squibb for approximately $74 billionJones Day advised Celgene Corporation (NASDAQ: CELG) in connection with the intellectual property and technology transactions aspects of its cash-and-stock merger with Bristol-Myers Squibb (NYSE: BMY) which has an equity value of approximately $74 billion.
  • Kyowa Hakko Kirin and BioWa successfully enforce patent rights on antibody technologyJones Day, on behalf of Japanese life sciences company Kyowa Hakko Kirin Company, Limited ("KHK") and its wholly-owned U.S. subsidiary, BioWa, successfully settled a patent infringement suit over three of KHK's patents that underlie KHK's award-winning POTELLIGENT® technology capable of producing therapeutic antibodies with dramatically improved potency and efficacy.
  • Kyowa Hakko Kirin defeats competitors in Patent Trial and Appeal Board challenge of patents on antibody technologyOn October 23, 2017, the Patent Trial and Appeal Board ("PTAB") issued a trio of decisions, unanimously declining to institute inter partes review ("IPR") of three patents owned by a Japanese pharmaceutical company represented by Jones Day, Kyowa Hakko Kirin Co., Ltd.
  • NGM develops global patent portfolio for beta-klotho antibodiesJones Day represents NGM Biopharmaceuticals, Inc. in the development of a global patent portfolio for antibodies to beta-klotho for the treatment of diabetes and other metabolic disorders.
  • Scynexis launches public offering of Common StockJones Day led a team that handled the IP diligence for a follow-on public offering of common stock for Scynexis, Inc., a Research Triangle Park, North Carolina, pharmaceutical company committed to the discovery, development, and commercialization of novel anti-infectives.
  • Perlan establishes global patent portfolio for ICAM1 antibodiesJones Day represents Perlan Therapeutics, Inc. in connection with the global patent portfolio for ICAM1 antibodies for the treatment of rhinovirus and other respiratory infections.
  • BioMarin establishes global patent portfolio for PAL technologyOn behalf of BioMarin Pharmaceutical, Inc., Jones Day assisted with global patent portfolio development and prosecution strategies regarding Prokaryotic Phenylalanine Ammonia-Lyase (PAL).
    • View All

    January 2018 Blog

    Declarations as New Evidence to Overcome § 325(d), PTAB Litigation Blog

    March 2017 Blog

    Including Functional Claim Language Helped Save Pozen’s VIMOVO® Patents, PTAB Litigation Blog

    Additional Speaking Engagements

    • April 20, 2019
      The Life Science Patent Landscape and Capital Markets - Updates in China and US, 2019 Chinese Bioscience Association Symposium
    • October 14, 2017
      Opportunities for Biosimilar Companies under the U.S. Legal System, 2017 Chinese Bioscience Association Annual Conference
    • May 8, 2015
      Lecture Presentation, Beijing Foreign Studies University, "Patent Operation in Biotechnological and Pharmaceutical Industries."

    Before sending, please note:

    Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.